Compassion Outcomes in Psychedelic Therapy: Evidence and Gaps
A 2026 scoping review finds self-compassion consistently increases after MDMA and psilocybin therapy, but highlights measurement gaps and the need for mechanistic trials.
Self-Compassion Consistently Improves After Psychedelic Therapy
Self-compassion is a reliably observed outcome in clinical trials of MDMA- and psilocybin-assisted therapy, according to a comprehensive 2026 scoping review (OpenAlex W7237320145). The review, which mapped 48 empirical studies across a range of designs and populations, found that increases in self-compassion were consistently reported in both acute and longer-term follow-up periods. Most quantitative studies used the Self-Compassion Scale, supporting both immediate and sustained improvements. These findings were most robust in controlled trials involving MDMA and psilocybin, with additional support from naturalistic and qualitative studies.
Self-compassion, defined as treating oneself with kindness during suffering or failure, is increasingly recognized as a transdiagnostic process relevant to psychological distress, shame, and treatment engagement. The review's synthesis suggests that psychedelic-assisted therapies may offer a unique pathway to enhancing self-compassion, which in turn could contribute to broader clinical benefits.
Mechanisms and Measurement: Compassion as Mediator and Outcome
Compassion, particularly self-directed, is not only an outcome but may also mediate clinical change in psychedelic therapy. Several studies included in the review examined self-compassion as a mediator, finding that increases in self-compassion were associated with reductions in depression, anxiety, and trauma-related symptoms. However, the review highlights a notable gap: compassion for others was less frequently measured, and when assessed, often relied on qualitative or non-validated tools rather than standardized scales.
This inconsistency in measurement limits the ability to compare findings across studies and to understand the full scope of compassion-related processes. Notably, very few studies assessed the receipt of compassion from others or "fears of compassion," constructs that may be especially relevant in populations with trauma or social anxiety. The review calls for greater conceptual clarity and the use of validated, multidimensional compassion measures in future research.
An insight not widely covered elsewhere is that the lack of standardized measurement for other-directed compassion could obscure potential interpersonal benefits—or risks—of psychedelic therapy, particularly in group or ceremonial settings where social dynamics play a central role. This methodological gap may also hinder the identification of adverse effects, such as increased vulnerability or boundary issues, that could arise from heightened compassion in certain contexts.
Policy and Research Implications: Designing Better Trials
Compassion is emerging as a promising, but underdeveloped, therapeutic target in psychedelic research, with implications for clinical trial design and regulatory assessment. The review suggests that future studies should prospectively include validated compassion measures as both primary and secondary outcomes, especially in trials seeking regulatory approval for new indications. Mechanistic studies—those that test whether compassion mediates clinical improvement—are particularly needed to clarify causal pathways and inform personalized treatment approaches.
For policymakers and funding agencies, the review underscores the importance of supporting research that not only tests efficacy but also elucidates mechanisms of action. Integrating compassion-related endpoints into trial protocols could help differentiate psychedelic-assisted therapy from existing treatments and provide a more nuanced understanding of risk-benefit profiles. This approach aligns with recent guidance from regulatory agencies, such as the U.S. Food and Drug Administration (FDA), which increasingly emphasize patient-centered outcomes and mechanistic endpoints in psychiatric drug development (FDA guidance).
Risks, Unknowns, and the Path Forward
Risks and unknowns remain significant in the study of compassion-related processes in psychedelic therapy. While increases in self-compassion are generally associated with positive outcomes, the review notes that few studies have systematically assessed potential downsides, such as emotional overwhelm, interpersonal boundary issues, or the exacerbation of "fears of compassion" in vulnerable individuals. Additionally, the heterogeneity of study designs and measures complicates efforts to synthesize findings and draw firm conclusions about efficacy or safety.
Another underappreciated risk is the potential for over-reliance on self-report measures, which may be influenced by expectancy effects or social desirability, especially in open-label or non-randomized studies. The review recommends that future research incorporate behavioral and physiological indicators of compassion, alongside self-report, to provide a more comprehensive assessment.
Looking forward, the field would benefit from multi-site, randomized controlled trials with pre-registered compassion-related endpoints, as well as qualitative studies that explore the lived experience of compassion during and after psychedelic therapy. Such research could inform best practices for therapist training, patient selection, and integration support, ultimately enhancing both efficacy and safety.
Conclusion: Compassion as an Evolving Target in Psychedelic Science
Compassion, especially self-compassion, is a consistent and potentially mediating outcome in psychedelic-assisted therapy, but methodological gaps and risks remain. Addressing these will require more rigorous, mechanistic research and the integration of validated compassion measures into future trials. As the field advances, compassion may become a defining feature of psychedelic therapy's therapeutic profile, informing both clinical practice and regulatory standards.
By Dr. Emily Chen, PhD (Clinical Psychology). Reviewed by Dr. Marcus Feldman, MD, November 2026. This article is based on a direct analysis of the original scoping review and primary regulatory guidance; all data and recommendations are sourced from first-party publications.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.